الصفحة 1
الصفحة 1
Human battle against obesity
Obesity is one of the most common preventable diseases and it is a medical condition in which excess fat has accumulated in the body, mostly in the subcutaneous tissues. Clinical obesity is considered to be present when a person has a body mass index of 30 or over. Obesity results from a chronic positive energy balance regulated by a complex interaction between endocrine tissues and the central nervous system, This activity reviews the pathophysiology of obesity, inflammatory markers secreted by excessive fat deposition in adipose tissue, and their effects on chronic diseases such as hypertension, diabetes, and dyslipidemia.
Enhancing the Dissolution Rate of Atorvastatin by Solid Dispersion Technique
In the last few decades, solid dispersion (SD) technology had been studied as an approach to produce an amorphous carrier to enhance the solubility, dissolution rate, and bioavailability of poorly water-soluble drugs. The use of suitable carrier and methodology in the preparation of SDs play a significant role in the biological behavior of the SDs. Atorvastatin is a statin group HMG-CoA reductase inhibitor drug that is commonly used to adverse cardiovascular events and to lower blood total cholesterol and LDL-cholesterol. the solubility of atorvastatin in water is very low (0.1 mg mL− 1), which results in reduced bioavailability. In order to enhance its solubility, we have prepared solid dispersions (SDs) of atorvastatin at different drug: polymer ratios (1:2, 1:10, 1:20,1:25 and 1:40), using polyethylene glycol 6000 as polymer and different preparation methods (co-precipitate and melting methods) The characterization of the SDs was performed using differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR) The solubility of AT was improved by the incorporation PEG6000.
